Arvinas Stock Forecast, Price & News

Arvinas' stock was trading at $44.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARVN stock has decreased by 43.6% and is now trading at $24.84.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arvinas or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Arvinas a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arvinas wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for Arvinas.

Arvinas, Inc. (NASDAQ:ARVN) released its quarterly earnings results on Tuesday, November, 10th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by $0.11. The company earned $7.60 million during the quarter, compared to analyst estimates of $5.68 million. Arvinas had a negative return on equity of 46.99% and a negative net margin of 403.77%.
View Arvinas' earnings history.

9 analysts have issued 12 month price objectives for Arvinas' stock. Their forecasts range from $45.00 to $75.00. On average, they anticipate Arvinas' stock price to reach $60.38 in the next twelve months. This suggests a possible upside of 143.1% from the stock's current price.
View analysts' price targets for Arvinas.

Some companies that are related to Arvinas include Hypera (HYPMY), Legend Biotech (LEGN), ChemoCentryx (CCXI), MorphoSys (MOR), FibroGen (FGEN), Apellis Pharmaceuticals (APLS), Deciphera Pharmaceuticals (DCPH), Eidos Therapeutics (EIDX), Agios Pharmaceuticals (AGIO), Nektar Therapeutics (NKTR), Alkermes (ALKS), Global Blood Therapeutics (GBT), Pacira BioSciences (PCRX), OPKO Health (OPK) and Axsome Therapeutics (AXSM).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Canaan Partners IX LLC (10.17%), BlackRock Inc. (5.91%), JPMorgan Chase & Co. (2.85%), State Street Corp (1.69%), ArrowMark Colorado Holdings LLC (0.81%) and Candriam Luxembourg S.C.A. (0.82%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am.
View institutional ownership trends for Arvinas.

ARVN stock was sold by a variety of institutional investors in the last quarter, including Canaan Partners IX LLC, UBS Asset Management Americas Inc., Point72 Asset Management L.P., Arrowstreet Capital Limited Partnership, Candriam Luxembourg S.C.A., State Street Corp, Voloridge Investment Management LLC, and AQR Capital Management LLC. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Ronald Peck, and Sean A Cassidy.
View insider buying and selling activity for Arvinas.

ARVN stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Boxer Capital LLC, Morgan Stanley, Sphera Funds Management LTD., BlackRock Inc., SG Americas Securities LLC, Cubist Systematic Strategies LLC, and Squarepoint Ops LLC. Company insiders that have bought Arvinas stock in the last two years include Briggs Morrison, Ian Taylor, Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas.

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARVN stock can currently be purchased for approximately $24.84.

Arvinas has a market capitalization of $1.01 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Arvinas employs 133 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]